US 12,415,072 B2
Spasticity treatment device and method
Samuel Colachis, Columbus, OH (US); Michael Darrow, Missouri City, TX (US); Eric C. Meyers, Columbus, OH (US); and Lauren Wengerd, Columbus, OH (US)
Assigned to BATTELLE MEMORIAL INSTITUTE, Columbus, OH (US)
Filed by Battelle Memorial Institute, Columbus, OH (US)
Filed on Oct. 13, 2022, as Appl. No. 17/965,279.
Claims priority of provisional application 63/256,375, filed on Oct. 15, 2021.
Prior Publication US 2023/0124842 A1, Apr. 20, 2023
Int. Cl. A61N 1/36 (2006.01); A61B 5/00 (2006.01); A61B 5/256 (2021.01); A61B 5/296 (2021.01); A61B 5/395 (2021.01); A61N 1/04 (2006.01)
CPC A61N 1/36003 (2013.01) [A61B 5/256 (2021.01); A61B 5/296 (2021.01); A61B 5/395 (2021.01); A61B 5/4836 (2013.01); A61B 5/6804 (2013.01); A61B 5/7425 (2013.01); A61N 1/0452 (2013.01); A61N 1/0456 (2013.01); A61N 1/0484 (2013.01); A61B 2562/046 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating spasticity, the method comprising:
measuring electromyography (EMG) signals from a target anatomy using electrodes contacting skin of the target anatomy;
identifying one or more spasm regions of the target anatomy based on the EMG signals;
displaying a representation of the target anatomy with the one or more spasm regions indicated on the representation; and
after displaying the representation of the target anatomy, delivering one or more injections of a spasticity-suppression pharmacological agent to the detected one or more spasm regions using a hypodermic needle.